File:Reversion of angiostatin angiogenesis inhibition by function blocking antibodies to IL-12.jpg
Size of this preview: 445 × 599 pixels. Other resolutions: 178 × 240 pixels | 357 × 480 pixels | 571 × 768 pixels | 1,200 × 1,615 pixels.
Original file (1,200 × 1,615 pixels, file size: 293 KB, MIME type: image/jpeg)
Captions
Captions
Add a one-line explanation of what this file represents
| Description |
English: A: Reversion of angiostatin angiogenesis inhibition by function blocking antibodies to IL-12. The matrigel angiogenesis assay was performed with the addition of factors as indicated by "+". The angiogenic stimulant was either Kaposi's sarcoma cell conditioned medium (KSCM) or VEGF (100 ng/ml) and TNFα (2 ng/ml) as indicated. AST = addition of angiostatin at 2.5 μg/ml. Anti-IL-12 = addition of 150 ng/ml of anti-IL12 antibodies. Means ± SEM are shown. *** = P < 0.001 (Mann-Whitney) when compared to controls (VEGF/TNFα or KSCM). N = indicates the number of samples in each group. Irrelevant antibodies had little effect on angiogenesis or AST inhibition (data not shown). B: Serum levels of IL-12 found in mice following weekly treatment with angiostatin. *** = P < 0.001 (Mann-Whitney) when compared to control. C: Histology of matrigel sponges. Gels removed at the end of the angiogenesis assay were fixed and paraffin embedded, 4 μM sections were obtained and hematoxylin-eosin stained. Addition of an angiogenic stimulus (KSCM shown) resulted in cellular infiltration and vascularization of the matrigel. The addition of AST strongly inhibited both cellular infiltration and angiogenesis. Antibodies to IL-12 (anti-IL-12) reversed the inhibitory effect of AST on cellular infiltration and vessel formation, but had little effect in control gels. Bar = 200 μm. Albini et al. Journal of Translational Medicine 2009 7:5 doi:10.1186/1479-5876-7-5 |
| Date | |
| Source | Angiostatin anti-angiogenesis requires IL-12: The innate immune system as a key target |
| Author | Adriana Albini* 1 , Claudio Brigati* 2 , Agostina Ventura3 , Girieca Lorusso1,4 , Marta Pinter4 , Monica Morini2 , Alessandra Mancino5 , Antonio Sica5,6 and Douglas M Noonan1,4 |
| Permission (Reusing this file) |
© 2009 Albini et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Other versions | Derivative works of this file: Angiostatin prevents sarcoma induced angiogenesis.jpg |
This file is licensed under the Creative Commons Attribution 2.0 Generic license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Thumbnail | Dimensions | User | Comment | |
|---|---|---|---|---|---|
| current | 12:22, 20 September 2009 | | 1,200 × 1,615 (293 KB) | CopperKettle (talk | contribs) | {{Information |Description={{en|1=A: Reversion of angiostatin angiogenesis inhibition by function blocking antibodies to IL-12. The matrigel angiogenesis assay was performed with the addition of factors as indicated by "+". The angiogenic stimulant was ei |
You cannot overwrite this file.
File usage on Commons
The following page uses this file:
